계명대학교 의학도서관 Repository

Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study

Metadata Downloads
Author(s)
Hyeong Kyu ParkKyoung-Ah KimKyung-Wan MinTae-Seo SohnIn Kyung JeongChul Woo AhnNan-Hee KimIe Byung ParkHo Chan ChoChoon Hee ChungSung Hee ChoiKang Seo ParkSeoung-Oh YangKwan Woo Lee
Keimyung Author(s)
Cho, Ho Chan
Department
Dept. of Internal Medicine (내과학)
Journal Title
Diabetes Obes Metab
Issued Date
2023
Volume
25
Issue
9
Keyword
SGLT2 inhibitordapagliflozinsulphonylureastype 2 diabetes
Abstract
Aims:
To evaluate the effect of dapagliflozin on body composition such as total body fat (BF) mass, abdominal visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) areas compared with glimepiride in Korean patients with type 2 diabetes.

Materials and methods:
This was a 52-week, multicentre, randomized, parallel-group, open-label, Phase IV (NCT02564926) study. Patients with inadequate glycaemic control (glycated haemoglobin ≥7.0% and <10.0%) on metformin monotherapy (≥1000 mg/day) were randomized 1:1 to receive dapagliflozin 10 mg/day or glimepiride 1-2 mg/day for 12 months as an add-on to metformin. Baseline and end of study body composition evaluations included dual-energy X-ray absorptiometry and abdominal computed tomography scans.

Results:
Of 124 enrolled patients from 14 centres, 121 received study treatment (dapagliflozin: 60; glimepiride: 61) and 106 (85.5%) completed the study. Over 52 weeks, the dapagliflozin group showed the following differences versus the glimepiride group: -2.59 kg BF mass, -1.94% BF%, -17.55 cm2 VAT area, -18.39 cm2 SAT area, -0.46% glycated haemoglobin, -18.25 mg/dl fasting blood glucose, -3.7 kg weight, -2.21 cm waist circumference, -1.37 kg/m2 body mass index, -6.81 mmHg systolic blood pressure and +657.71 ng/ml in adiponectin; all were statistically significant. Both groups had similar incidences of adverse events; however, hypoglycaemic events were mainly (12 of 15) reported in the glimepiride group.

Conclusion:
Dapagliflozin reduced total BF mass, abdominal VAT and SAT areas, and showed better glycaemic control than glimepiride. Being safe and well-tolerated, dapagliflozin appears to be a more favourable alternative to sulphonylureas as add-on therapy after metformin monotherapy failure in Korean patients with type 2 diabetes.
Keimyung Author(s)(Kor)
조호찬
Publisher
School of Medicine (의과대학)
Type
Article
ISSN
1463-1326
Source
https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15164
DOI
10.1111/dom.15164
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/45198
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.